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Abstract  
Objective.  The objective of this study and the reason that encouraged 
us to carry out this work was to characterize the adverse events reported 
during the treatment with Heberprot-P® in different health institution/
centers.  Materials and Methods: Longitudinal, multicenter, post-
marketing follow-up study of Heberprot-P®. Intensive surveillance was 
used as PS (pharmacosurveillance) method. The following variables 
were considered: presence or absence of AEs (adverse events); most 
frequently reported AEs; affected organ system; serious AE according 
to cause conditioning both the event severity and type, and severity 
of ADRs (adverse drug reactions) and causality of AE reported as 
serious.    Results:  The presence of at least one AE was reported in 
260 patients (59.1%).  Burning sensation and pain in injection site, 
chills and shivering, were the four most frequently reported adverse 
events. A total of 11 events were identified as serious.  Conclusions : 
The intensive PS of the drug should be continued since all the routine 
medical practice data that could be contributed are essential for the 
purpose of enriching the drug’s safety profile. 
Keywords:  Adverse drug reaction, Pharmacosurveillance, Diabetic 
foot ulcer .
Resumen
Objetivo: Caracterizar los eventos adversos reportados durante el 
tratamiento con     Heberprot-P®en diferentes instituciones de salud 
fue el objetivo del estudio y lo quenos motivó a efectuar éste trabajo.
Materiales y metodos:  Estudio longitudinal y multicéntrico de 
seguimiento post-comercialización de Heberprot-P® y se empleó 
como método de FV, la vigilancia intensiva. se utilizaron las variables 
siguientes: Presencia o no de EA, EA más frecuentes reportados, 
sistema de órganos afectado, EA grave según motivo que condicionó 
la gravedad del evento y tipo de evento y la gravedad de las RAM 
y causalidad del EA reportado como grave. Resultados: En 269 
pacientes (59,1%) se reportó la presencia de al menos un EA. El ardor y 
el dolor en el sitio de inyección, las tiriteras y los escalofríos fueron los 
cuatro eventos que más reportes presentaron. Se determinaron como 
graves 11 eventos. Conclusiones: Se debe continuar la FV intensiva 
del fármaco, ya que son necesarios todos los datos que se aporten 
en las condiciones de la práctica médica habitual, con la finalidad de 
enriquecer el perfil de seguridad del mismo.
Palabras claves: Reacción Adversa a Medicamento, Farmacovigilancia, 
Úlcera de Pie Diabético.
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Caracterización de los eventos adversos reportados durante el tratamiento con 
Heberprot-P® en cuatro provincias de Cuba
Introduction 
Medications are the medical technology most frequently 
used currently. Their development has modified the 
manner in which diseases are prevented and treated, 
favoring changes in their epidemiological profile in 
various regions of the world. However, despite the 
advantages they offer, there is increasing evidence that 
adverse drug reactions (ADRs) are a frequent, though 
often preventable cause of disease, disability, or even 
death, to the point of being included on the list of the 10 
main causes of death in some countries. 1
The surveillance of medication safety can potentially 
promoting inspire trust in regards to their use in both 
patients and health care professionals, while being 
regarded as an essential element to achieve a safe use of 
drugs and high-quality medical care.  
Post-marketing investigations with biological and 
biotechnological products are a challenge in the sense 
that their effectiveness and safety may be affected 
by several factors, such as the molecular structure 
complexity, heterogenicity of molecular composition, 
sensitivity to changes in physical conditions, and 
immunogenicity, hence the need for a comprehensive 
pre-clinical and clinical program and an adequate post-
marketing pharmacosurveillance (PS). 2,3 
 
The Centro para el  Desarrollo  de la Farmacoepidemiología 
(Center for Pharmaco-epidemiology Development) 
(CDF, for its acronym in Spanish) undertook the 
responsibility for performing the follow-up of 
Heberprot-P®, as requested and under contract with the 
Centro de Ingeniería Genética y Biotecnología (Genetic 
Engineering and Biotechnology Center) (CIGB, for its 
acronym in Spanish) for the purpose of determining its 
effectiveness, identifying and quantifying its adverse 
events (AEs), particularly those not known before its 
registration, and determining possible risk factors or 
effect modifies, as well as knowing the effects of the 
drug from the perspective of patients in non-controlled 
situations of regular clinical practice. 
A Heberprot-P® is prescribed for the treatment of 
diabetic foot ulcer (DFU). In previous phase I, II, and III 
clinical trials, the intralesional administration of the drug 
was shown to mitigate the consequences of neurogenic 
ischemia and protect peripheral soft tissues, as well as 
to contribute to the formation of granulation tissue and 
favoring its healing action, effect that is associated to a 
reduction in the number of amputations. 4
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The medication was introduced to the Cuban Basic 
Schedule of Essential Drugs in April 2007. From that date 
on, an expansion strategy was started in the Sistema 
Nacional de Salud (National Health System) (SNS, for its 
acronym in Spanish), aimed at implementing its use and 
integral management for DFU in all the diabetic patient 
care services/centers.5 
Characterizing the adverse events reported during the 
treatment with Heberprot-P® in various healthcare 
institutions was the objective of this study and the 
reason that encouraged us to carry out this work.
Materials and Method 
An observational, analytical, prospective, longitudinal, 
multicenter study Heberprot-P® post-marketing follow-
up was carried out, using an intensive surveillance as PS 
method. 
The study was undertaken in the period stretching from 
June 2007 to March 2010, after the national expansion 
of Heberprot-P® in the SNS. All Cuban patients of any 
sex, aged 18 or over, and with clinical diagnosis of DFU 
of different Wagner grades6 , were considered eligible 
and received the product at healthcare institutions 
in the provinces of Pinar del Río, Havana, Havana 
City and Matanzas. The study group comprised 455 
patients. Individuals with non-compensated chronic 
diseases, history of or suspected malignant diseases, 
hypersensitivity to the product or any of its components, 
pregnant or lactating, or with ulcers affecting an area < 
1 cm2 were excluded.  The criteria considered included 
cessation of treatment, overgranulation of lesion, 
voluntary withdrawal, presence of serious AE, extension 
of ulcerative area, and indication of major amputation.
 
In order to fulfill the specified objective, the following 
variables were used: presence or absence of AEs; most 
frequently reported AEs; affected organ system; serious 
AEs according to the type of event and cause that 
conditioned severity, and existing causality relationship 
of the various AEs reported as serious.
To evaluate the causality of ADR reports, the most 
frequently used method is the qualitative and 
quantitative algorithm of Karch and Lasagna, relating 
5 categories: definite, probable, possible, conditional, 
and non related, and refers to the  casual relationship 
between drug treatment and the occurrence of adverse 
reactions in the case of individual suspected ARs.7
Besides causality, the magnitude of the adverse event 
effect on an individual is also related to the severity of 
the AE which can then be classified according the World 
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Health Organization (WHO) as mild, moderate, severe of 
fatal, depending on whether it affects or not and to what 
degree the activities of daily living.8
The assessment of severity requires an individualized 
study of the adverse event, as well as of the reaction 
duration and intensity. 
Another classification used is the one relating results and 
their consequences, which can be serious or non serious. 
The categories were established on the basis of the 
classification of ADR severity by the WHO. 7
Events were classified according to their severity and 
causality for serious AEs pursuant to the provisions set 
forth by the Standards and Procedures of the Cuban 
pharmacosurveillance system.   The extent of organ 
system involvement was determined in accordance to 
the WHO terminology dictionary, 2008 edition. 10
The serious AEs were reported within 24 hours to the 
provincial pharmaco-epidemiologist who, in turn, 
notified the CDF. The case was discussed first in each 
province by the provincial PS commission and then 
by a group of experts established for the purpose of 
this investigation and that comprised specialists in 
angiology and vascular surgery, cardiologists, clinicians, 
qualified staff from the PS department of the CIGB and 
CDF investigators, all of whom had access to the post-
marketing study.
The variables related to safety were subjected to 
descriptive analysis. The reporting frequency of AEs was 
calculated taking as denominator the total of patients 
exposed to intensive surveillance during the study 
period.
A data entering model was designed to collect all the 
necessary information that was later transferred to a 
database created in the Statistical Package for Social 
Sciences (SPSS), Version 11.5, with the information from 
the corresponding data collection logbooks.
Information was presented in tabular form
Results 
The presence of at least one AE was reported in 269 
patients (59.1%). In total, 1,527 events were reported and 
grouped into 48 different types. Of these, 92.4% (1,411) 
were classified as mild and 6.9% (105) as moderate. 
Burning sensation and pain the injection site, chills and 
shivering, were the most frequently reported adverse 
events (see Table 1). 
Biomedicine 
The most frequently involved organ system was the 
application site (55.0%), followed by general body 
disorders (31.3%) (Table 2). 
 
A total of 11 adverse events were classified as serious 
(0.7%) that correspond to the same number of patients, 
four of which had a fatal outcome and seven were either 
life threatening, led to permanent sequels or prolonged 
the patient hospitalization (see Table 3). 
Of the 11 reported AEs, 5 were classified as possible, 4 as 
conditional, 1 as probable and the remaining one as non 
related (see Table 4). 
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Discussion   
The most frequent AEs correspond to those reported in 
the clinical essays (CEs) developed for the product 4 and 
in post-marketing studies. 11, 12, 13
During the previous clinical essays, pain and burning 
sensation on the application site are reported as related 
to administration method. Besides, chills and shivering 
where the only AEs where a definite or probable 
dose-dependent causal relationship was found with 
the use of Heberprot-P®. A pyrogenic reaction was 
ruled out because the product is released as “free of 
pyrogens” specification. It is possible to speculate 
whether the epidermal growth factor (EGF), at the 
drug concentrations reached after the intralesional 
administration, may interact with the thermoregulatory 
centers in the hypothalamus, in the same manner that 
other cytokines do. A direct action of EGF on the SNS has 
been reported after its intraventricular injection.
  
The types of reported events and the product 
administration method conditioned that the most 
affected system organs were the application site, 
followed by general body disorders. Similar results were 
described by other authors.11, 15, 16, 17, 18
Domínguez Caballero10 and Ramírez Calzadilla  in 
investigations conducted in other provinces of the 
country, reported a profile of serious AEs similar to the 
In the causality analysis, events such as myocardial 
infarction, non-compensated heart failure, and acute 
lung edema were classified as conditional. The literature 
on the subject indicates that diabetes mellitus is one of 
the major risk factors for cardiovascular diseases,20, 21, 22, 23 
and the presence of DFU adds an additional risk, both in 
terms of general mortality as well as mortality due to an 
acute myocardial infarction.22
To provide an adequate and correct judgment on this 
matter, more data were needed.
A possible causality relationship was attributes to local 
infection, since it represents one of the most frequently 
reported serious events in the clinical essays of this 
product. This event may also be explained by the basic 
disease of the patient and the disease that cause the 
product to be administered (DFU). 
Glottic edema associated to dyspnea, erythrocianosis, 
and mild precordialgia was considered as probable 
since it was a reasonable temporary side effect related 
to the drug administration (single dose) and it unlikely 
to be attributed to the concurrent disease. The 
patient was receiving a treatment with ceftazidime, 
but the temporary relationship was feasible with the 
administration of Heberprot-P®. 
Acute gastroenterocolitis was classified as related since 
it occurred in a patient and the time sequence between 
the event and the last administration of the drug, did 
not justify its occurrence and could be explained by the 
underlying disease.
Heberprot-P® was recently launched in the market and 
some of these AEs are not mentioned in the product 
information. 24
Conclusions.
The PS of the medication should be continued since all 
the data are needed that contribute to the conditions 
of physicians’ daily medical practice, with the aim of 
improving the knowledge on its safety profile.   
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